SCHEMBL2301152

SCHEMBL2301152

Cc1ccc(Cl)cc1NC(=O)c1ccccc1C(=O)c1ccc2nc(NC(=O)O)[nH]c2c1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ RAF1 P04049 5/20 0.57
▸ BRAF P15056 5/20 0.57
▸ LMNA P02545 3/20 0.50
▸ HTT P42858 3/20 0.50
▸ ABL1 P00519 3/20 0.50
▸ ALDH1A1 P00352 2/20 0.50
▸ ABCC4 O15439 1/20 0.50
▸ USP2 O75604 1/20 0.50
▸ CYP1A2 P05177 1/20 0.50
▸ CYP2C9 P11712 1/20 0.50
▸ KDR P35968 1/20 0.50
▸ HIF1A Q16665 1/20 0.50
▸ NPSR1 Q6W5P4 2/20 0.49
▸ XIAP P98170 1/20 0.48
▸ NPC1 O15118 4/20 0.47
▸ RAB9A P51151 4/20 0.47
▸ POLB P06746 3/20 0.47
▸ KDM4E B2RXH2 2/20 0.47
▸ MAPT P10636 2/20 0.47
▸ NPY1R P25929 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2299292 0.91 RAF1 (0.55) RAF1BRAFLMNAHTTABL1
SCHEMBL2297946 0.89 RAF1 (0.57) RAF1BRAFLMNAHTTABL1
SCHEMBL1467642 0.85 NPSR1 (0.46) RAF1BRAFLMNAHTTALDH1A1
SCHEMBL3475822 0.85 RAF1 (0.59) RAF1BRAFLMNAHTTABL1
SCHEMBL2300130 0.83 RAF1 (0.57) RAF1BRAFLMNAHTTABL1
SCHEMBL2357346 0.82 RAF1 (0.54) RAF1BRAFLMNAHTTABL1
SCHEMBL2296483 0.82 RAF1 (0.56) RAF1BRAFLMNAHTTABL1
SCHEMBL2297881 0.81 RAF1 (0.58) RAF1BRAFLMNAHTTABL1
SCHEMBL3848804 0.81 NPSR1 (0.48) LMNAHTTALDH1A1NPSR1NPC1
SCHEMBL2297867 0.80 RAF1 (0.54) RAF1BRAFLMNAHTTABL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2101759-B1 METHODS OF USING MEK INHIBITORS EXELIXIS INC (US) 2018-10-10 — — EP claimed
US-7846959-B2 Raf modulators and methods of use EXELIXIS, INC. (US) 2010-12-07 — — US claimed
EP-2139483-B9 COMBINATION THERAPIES COMPRISING A QUINOXALINE INHIBITOR OF PI3K-ALPHA FOR USE IN THE TREATMENT OF CANCER EXELIXIS INC (US) 2014-05-21 — — EP disclosed
EP-2139483-B1 COMBINATION THERAPIES COMPRISING A QUINOXALINE INHIBITOR OF PI3K-ALPHA FOR USE IN THE TREATMENT OF CANCER EXELIXIS INC (US) 2013-09-18 — — EP disclosed
US-7999006-B2 Anticancer agents; mitogen-activated protein kinases (MEK) EXELIXIS, INC. (US) 2011-08-16 — — US disclosed
Send feedback